

Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients

NCT06922045

Status	RECRUITING
Phase	Phase 3
Sponsor	Jiangsu BioJeTay Biotechnology Co., Ltd.
Enrollment	32 participants

Key Eligibility Criteria

Inclusion (7)

- aged 70 years of age.
 - Hemophilia A or B patients.
 - Peak historical inhibitor titer \leq 5 BU and a positive inhibitor test when enrolled.
 - Establish proper venous access.
 - There were at least 3 bleeding events that required treatment occurred in the past 6 months before screening.
- ... and 2 more (see full listing online)

Exclusion (15)

- Have any coagulation disorder other than hemophilia.
 - Plan to receive prophylactic treatment of coagulation factor during the trial.
 - Patients plan to receive Emicizumab during the trial.
 - Patients received anticoagulant or antifibrinolytic therapy 7 days before the first administration or plan to receive these drugs during the trial.
 - Have a history of arterial and/or venous thrombotic events.
- ... and 10 more (see full listing online)

Locations (18 total)

Anhui Provincial Hospital, Hefei, Anhui, China
Lanzhou University First Hospital, Lanzhou, Gansu, China
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
... and 15 more locations